DE69824039T2
(de)
|
1997-12-08 |
2005-08-18 |
Lexigen Pharmaceuticals Corp., Lexington |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
PL343462A1
(en)
*
|
1998-04-15 |
2001-08-13 |
Lexigen Pharm Corp |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
BR0013231A
(pt)
*
|
1999-08-09 |
2002-07-23 |
Lexigen Pharm Corp |
Complexos citocina-anticorpo múltiplos
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
ES2269366T3
(es)
*
|
2000-02-11 |
2007-04-01 |
Merck Patent Gmbh |
Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
WO2001087329A1
(en)
*
|
2000-05-15 |
2001-11-22 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivate
|
DE60129695T2
(de)
*
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
AU2001290312A1
(en)
*
|
2000-10-16 |
2002-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Peg-modified erythropoietin
|
ATE505204T1
(de)
*
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
CN100528235C
(zh)
*
|
2000-12-20 |
2009-08-19 |
霍夫曼-拉罗奇有限公司 |
红细胞生成素共轭物
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
EP1234583A1
(de)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-Konjugate des HGF-NK4
|
BR0207854A
(pt)
*
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
DE60239454D1
(de)
*
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
KR100467751B1
(ko)
|
2001-12-03 |
2005-01-24 |
씨제이 주식회사 |
생체내 에리스로포이에틴 활성이 증진된 융합단백질
|
ES2381025T3
(es)
|
2001-12-04 |
2012-05-22 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada
|
EP2324834B1
(de)
*
|
2001-12-06 |
2019-05-08 |
Fibrogen, Inc. |
Verfahren zur Steigerung des endogenen Erythropoietins
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
AU2003218045A1
(en)
|
2002-03-11 |
2003-09-29 |
Ortho Mcneil Pharmaceutical, Inc |
Methods for shp1 mediated neuroprotection
|
CA2491567A1
(en)
*
|
2002-07-01 |
2004-01-08 |
The Kenneth S. Warren Institute, Inc. |
Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
|
CA2492775C
(en)
|
2002-07-24 |
2011-06-21 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
US7459435B2
(en)
*
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
CA2498319A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
US20050176627A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Anthony Cerami |
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
|
BR0314107A
(pt)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Método de produção de derivados de hidroxialquil amido
|
US7459436B2
(en)
*
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
JP4494977B2
(ja)
*
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
US7553930B2
(en)
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
AU2004227937B2
(en)
|
2003-03-31 |
2007-09-20 |
Xencor, Inc |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7279174B2
(en)
*
|
2003-05-08 |
2007-10-09 |
Advanced Cardiovascular Systems, Inc. |
Stent coatings comprising hydrophilic additives
|
BRPI0411160A
(pt)
*
|
2003-05-12 |
2006-07-11 |
Affymax Inc |
novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
|
EP1628686A2
(de)
*
|
2003-05-12 |
2006-03-01 |
Affymax, Inc. |
Abstandsteil für mit poly (ethylenglycol) modifizierten peptide
|
ATE428727T1
(de)
*
|
2003-05-12 |
2009-05-15 |
Affymax Inc |
Neue, an den erythropoietinrezeptor bindende peptide
|
MXPA05012313A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos que se unen al receptor de eritropoyetina.
|
KR20060032140A
(ko)
*
|
2003-05-30 |
2006-04-14 |
센토코 인코포레이티드 |
트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
|
US7662607B2
(en)
*
|
2003-07-30 |
2010-02-16 |
New Century Pharmaceuticals, Inc. |
Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EA010650B1
(ru)
*
|
2003-09-29 |
2008-10-30 |
Уоррен Фармасьютикалз, Инк. |
Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
|
EP1675871A2
(de)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
|
EP1696947B1
(de)
*
|
2003-12-19 |
2014-02-26 |
F.Hoffmann-La Roche Ag |
Verwendung von erythropoietin zur behandlung von störungen des eisen verteilung in chronische entzündliche darmerkrankungen
|
EP1548031A1
(de)
*
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Naturidentischer Erythropoietin
|
PT1699821E
(pt)
*
|
2003-12-31 |
2012-08-23 |
Merck Patent Gmbh |
Proteína de fusão fc-eritropoietina com farmacocinética melhorada
|
JP5015608B2
(ja)
*
|
2004-01-21 |
2012-08-29 |
ネクター セラピューティクス |
プロピオン酸末端ポリマーの調製方法
|
ZA200606216B
(en)
*
|
2004-02-02 |
2007-11-28 |
Ambrx Inc |
Modified human interferon polypeptides and their uses
|
WO2005092928A1
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US7253650B2
(en)
|
2004-05-25 |
2007-08-07 |
International Business Machines Corporation |
Increase productivity at wafer test using probe retest data analysis
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
JP2008519858A
(ja)
*
|
2004-11-11 |
2008-06-12 |
アフィーマックス・インコーポレイテッド |
エリスロポエチンレセプターに結合する新規ペプチド
|
CA2595695A1
(en)
|
2005-01-25 |
2006-08-03 |
Cell Therapeutics, Inc. |
Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life
|
WO2006089228A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US20070072795A1
(en)
*
|
2005-09-28 |
2007-03-29 |
Anton Haselbeck |
Treatment of neurodegenerative disorders
|
PL1931704T3
(pl)
*
|
2005-10-04 |
2011-06-30 |
Zymogenetics L L C |
Wytwarzanie i oczyszczanie IL-29
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
US8053569B2
(en)
*
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
US20070092486A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Avigenics, Inc. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
JP5528710B2
(ja)
*
|
2006-02-28 |
2014-06-25 |
オリガシス コーポレイション |
アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
|
WO2007108505A1
(ja)
|
2006-03-22 |
2007-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
エリスロポエチン溶液製剤
|
CA2659990C
(en)
*
|
2006-08-04 |
2016-03-22 |
Prolong Pharmaceuticals, Inc. |
Polyethylene glycol erythropoietin conjugates
|
US8497246B2
(en)
*
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
JP2010510794A
(ja)
*
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
TW201206954A
(en)
*
|
2007-02-02 |
2012-02-16 |
Amgen Inc |
Hepcidin, hepcidin antagonists and methods of use
|
US20090011040A1
(en)
*
|
2007-05-02 |
2009-01-08 |
Naash Muna I |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
AR067537A1
(es)
*
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Purificacion de polipeptidos pegilados
|
AR067536A1
(es)
*
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
|
US8974791B2
(en)
|
2007-07-27 |
2015-03-10 |
Armagen Technologies, Inc. |
Methods and compositions for increasing α-L-iduronidase activity in the CNS
|
EP2205280B1
(de)
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmazeutische formulierungen
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
WO2009089542A2
(en)
|
2008-01-11 |
2009-07-16 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
AU2009206306B2
(en)
|
2008-01-25 |
2013-06-06 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
SG187427A1
(en)
|
2008-04-14 |
2013-02-28 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
EP2816059A1
(de)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-Hepcidin-Antikörper und Verfahren zu ihrer Verwendung
|
CA2953975C
(en)
|
2008-06-27 |
2019-11-26 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
CN102232085A
(zh)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
EP3693014A1
(de)
|
2008-11-13 |
2020-08-12 |
The General Hospital Corporation |
Verfahren und zusammensetzungen zur regulierung der eisenhomöostase durch modulierung der bmp6-aktivität
|
KR101546563B1
(ko)
|
2008-12-09 |
2015-08-28 |
할로자임, 아이엔씨 |
연장된 가용성 ph20 폴리펩티드 및 그의 용도
|
WO2010108048A2
(en)
|
2009-03-18 |
2010-09-23 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
JP5813638B2
(ja)
|
2009-07-30 |
2015-11-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
可動クロマトグラフィーカラムセパレータ
|
WO2011024025A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Avesthagen Limited |
An erythropoietin analogue and a method thereof
|
IN2012DN03219A
(de)
|
2009-09-17 |
2015-10-23 |
Baxter Healthcare Sa |
|
CA2775012A1
(en)
*
|
2009-09-23 |
2011-03-31 |
Biogenerix Ag |
Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
|
SI2485761T1
(sl)
|
2009-10-09 |
2019-05-31 |
Armagen, Inc. |
Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
|
US9662271B2
(en)
|
2009-10-23 |
2017-05-30 |
Amgen Inc. |
Vial adapter and system
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
SG10201908916UA
(en)
*
|
2010-04-27 |
2019-11-28 |
Scil Tech Gmbh |
Stable MIA/CD-RAP formulations
|
EA032537B1
(ru)
|
2010-06-07 |
2019-06-28 |
Эмджен Инк. |
Способ работы устройства для доставки лекарственного средства
|
EP2595624B1
(de)
|
2010-07-20 |
2018-01-31 |
Halozyme, Inc. |
Verfahren zur linderung bzw. vermeidung der nebenwirkungen im zusammenhang mit der verabreichung eines anti-hyaluronan-mittels
|
EP2616101B1
(de)
|
2010-09-14 |
2014-07-09 |
F.Hoffmann-La Roche Ag |
Verfahren zur reinigung von pegyliertem erythropoetin
|
EP2671074A1
(de)
|
2011-02-02 |
2013-12-11 |
F. Hoffmann-La Roche AG |
Chromatographiesäulenunterstützung
|
EP2672958A1
(de)
|
2011-02-08 |
2013-12-18 |
Halozyme, Inc. |
Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
|
WO2012135315A1
(en)
|
2011-03-31 |
2012-10-04 |
Amgen Inc. |
Vial adapter and system
|
LT2699293T
(lt)
|
2011-04-20 |
2019-04-25 |
Amgen Inc. |
Automatinio purškimo prietaisas
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
EP3335747B1
(de)
|
2011-10-14 |
2021-04-07 |
Amgen Inc. |
Injektor und verfahren zur montage
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
JP6266529B2
(ja)
|
2011-12-02 |
2018-01-24 |
アーマジェン・インコーポレイテッドArmagen, Inc. |
Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物
|
PT3130347T
(pt)
|
2011-12-30 |
2019-12-10 |
Halozyme Inc |
Variantes de polipéptidos de ph20, suas formulações e utilizações
|
PT2833905T
(pt)
|
2012-04-04 |
2018-08-06 |
Halozyme Inc |
Terapia de combinação com hialuronidase e um taxano dirigido a tumor
|
CN102816227A
(zh)
*
|
2012-08-30 |
2012-12-12 |
深圳赛保尔生物药业有限公司 |
回收促红细胞生成素的方法
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
ES2780395T3
(es)
|
2012-11-21 |
2020-08-25 |
Amgen Inc |
Dispositivo de administración de fármacos
|
MX359794B
(es)
|
2013-03-15 |
2018-10-10 |
Intrinsic Lifesciences Llc |
Anticuerpos anti-hepcidina y usos de los mismos.
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
US10492990B2
(en)
|
2013-03-15 |
2019-12-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
CN113559363B
(zh)
|
2013-03-22 |
2023-10-31 |
美国安进公司 |
注射器及装配方法
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
EP3760639A1
(de)
|
2013-09-08 |
2021-01-06 |
Kodiak Sciences Inc. |
Zwitterionische polymerkonjugate
|
JP7051293B2
(ja)
|
2013-10-24 |
2022-04-11 |
アムジエン・インコーポレーテツド |
温度感知制御を伴う薬剤送達システム
|
US11097055B2
(en)
|
2013-10-24 |
2021-08-24 |
Amgen Inc. |
Injector and method of assembly
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
SG11201609219QA
(en)
|
2014-05-07 |
2016-12-29 |
Amgen Inc |
Autoinjector with shock reducing elements
|
KR102506249B1
(ko)
|
2014-06-03 |
2023-03-03 |
암겐 인코포레이티드 |
약물 전달 시스템 및 사용 방법
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3186281B1
(de)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
|
WO2016049036A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
CA2957960C
(en)
|
2014-10-14 |
2023-08-22 |
Amgen, Inc. |
Drug injection device with visual and audible indicators
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
EP3233159B1
(de)
|
2014-12-19 |
2020-03-04 |
Amgen Inc. |
Medikamentenabgabevorrichtung mit beweglicher taste oder bedienfeld
|
JP6716566B2
(ja)
|
2014-12-19 |
2020-07-01 |
アムジエン・インコーポレーテツド |
近接センサ付き薬物送達装置
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
ES2748750T3
(es)
|
2015-02-17 |
2020-03-17 |
Amgen Inc |
Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
|
ES2905870T3
(es)
|
2015-02-27 |
2022-04-12 |
Amgen Inc |
Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
US11351308B2
(en)
|
2015-12-09 |
2022-06-07 |
Amgen Inc. |
Auto-injector with signaling cap
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
EP3721922B1
(de)
|
2016-03-15 |
2022-05-04 |
Amgen Inc. |
Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen
|
CN105820232B
(zh)
*
|
2016-04-08 |
2019-05-17 |
昂德生物药业有限公司 |
单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
AU2017263558B2
(en)
|
2016-05-13 |
2022-12-22 |
Amgen Inc. |
Vial sleeve assembly
|
US11238150B2
(en)
|
2016-05-16 |
2022-02-01 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
US11541176B2
(en)
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
WO2018004842A1
(en)
|
2016-07-01 |
2018-01-04 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
CN109415427A
(zh)
|
2016-07-15 |
2019-03-01 |
豪夫迈·罗氏有限公司 |
用于纯化聚乙二醇化的促红细胞生成素的方法
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
JP7064501B2
(ja)
|
2017-02-17 |
2022-05-10 |
アムジエン・インコーポレーテツド |
無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
|
AU2018221351B2
(en)
|
2017-02-17 |
2023-02-23 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
CA3050927A1
(en)
|
2017-03-06 |
2018-09-13 |
Brian Stonecipher |
Drug delivery device with activation prevention feature
|
IL268478B2
(en)
|
2017-03-07 |
2023-10-01 |
Amgen Inc |
Inserting a needle using super pressure
|
JP2020509837A
(ja)
|
2017-03-09 |
2020-04-02 |
アムジエン・インコーポレーテツド |
薬剤送達装置のための挿入機構
|
CN110446499A
(zh)
|
2017-03-20 |
2019-11-12 |
豪夫迈·罗氏有限公司 |
一种体外糖基工程化红细胞生成刺激蛋白的方法
|
CN110446512B
(zh)
|
2017-03-28 |
2022-03-18 |
美国安进公司 |
柱塞杆和注射器组件系统以及方法
|
EP3634546A1
(de)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Drehmomentangetriebene arzneimittelabgabevorrichtung
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
CN111107870A
(zh)
|
2017-06-22 |
2020-05-05 |
催化剂生物科学公司 |
经修饰的膜型丝氨酸蛋白酶1(mtsp-1)多肽及其使用方法
|
MX2019015472A
(es)
|
2017-06-22 |
2020-02-19 |
Amgen Inc |
Reduccion del impacto/choque de la activacion del mecanismo.
|
WO2018237225A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
|
EP3651832B1
(de)
|
2017-07-14 |
2023-12-13 |
Amgen Inc. |
Nadeleinführ-retraktionssystem mit doppeltorsionsfedersystem
|
MA49626A
(fr)
|
2017-07-21 |
2020-05-27 |
Amgen Inc |
Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
|
WO2019022951A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
|
WO2019022950A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
|
EP3664863A2
(de)
|
2017-08-09 |
2020-06-17 |
Amgen Inc. |
Hydraulisch-pneumatisches druckkammer-arzneimittelabgabesystem
|
MA49897A
(fr)
|
2017-08-18 |
2020-06-24 |
Amgen Inc |
Injecteur sur-corps avec patch adhésif stérile
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
CN111132711B
(zh)
|
2017-10-06 |
2022-07-01 |
安进公司 |
带有联锁组件的药物递送装置及相关组装方法
|
EP3694578A1
(de)
|
2017-10-09 |
2020-08-19 |
Amgen Inc. |
Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
|
WO2019090079A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
System and approaches for sterilizing a drug delivery device
|
WO2019089178A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
WO2019090303A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
CA3079665A1
(en)
|
2017-11-10 |
2019-05-16 |
Amgen Inc. |
Plungers for drug delivery devices
|
WO2019099324A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
JP7137625B2
(ja)
|
2017-12-29 |
2022-09-14 |
エフ.ホフマン-ラ ロシュ アーゲー |
Peg化タンパク質組成物を提供するための方法
|
WO2019129877A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Process for providing pegylated protein composition
|
KR102497097B1
(ko)
|
2017-12-29 |
2023-02-06 |
에프. 호프만-라 로슈 아게 |
페길화 단백질 조성물의 제공 방법
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
CA3103682A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
US20210228815A1
(en)
|
2018-07-24 |
2021-07-29 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
EP3826701A1
(de)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Ausgabevorrichtung zur verabreichung von arzneimitteln
|
EP3829692A1
(de)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Flüssigkeitsweganordnungen für wirkstofffreisetzungsvorrichtung
|
EP3613486B1
(de)
*
|
2018-08-24 |
2020-10-07 |
UGA Biopharma GmbH |
Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
|
MA53724A
(fr)
|
2018-09-24 |
2021-12-29 |
Amgen Inc |
Systèmes et procédés de dosage interventionnel
|
AU2019350660A1
(en)
|
2018-09-28 |
2021-03-18 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
AR116679A1
(es)
|
2018-10-02 |
2021-06-02 |
Amgen Inc |
Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna
|
EP3860686A1
(de)
|
2018-10-05 |
2021-08-11 |
Amgen Inc. |
Medikamentenabgabevorrichtung mit dosisindikator
|
SG11202103800RA
(en)
|
2018-10-15 |
2021-05-28 |
Amgen Inc |
Drug delivery device having damping mechanism
|
CA3109988A1
(en)
|
2018-10-15 |
2020-04-23 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
MA54057A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
|
EP3873566A1
(de)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Vorrichtung zur verabreichung von medikamenten mit teilweisem rückzug des medikamentenabgabeelements
|
WO2020092056A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial needle retraction
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
US20220160972A1
(en)
|
2019-04-24 |
2022-05-26 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
CA3148261A1
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
US20230331798A1
(en)
|
2020-09-22 |
2023-10-19 |
Jecho Laboratories, Inc. |
Glycosylation-modified erythopoietin and use thereof
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
IL308169A
(en)
|
2021-05-10 |
2024-01-01 |
Chiome Bioscience Inc |
Purification method of an antibody compound
|
WO2022246055A1
(en)
|
2021-05-21 |
2022-11-24 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
CN116492448A
(zh)
*
|
2023-04-12 |
2023-07-28 |
深圳赛保尔生物药业有限公司 |
负载peg-epo及间充质干细胞的组合物、药物及其制备方法
|